Christina Schellenbacher

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity.

Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity.

Journal: Vaccine
Published: February 16, 2019

Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).

Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).

Journal: PloS one
Published: October 17, 2016

Developments in L2-based human papillomavirus (HPV) vaccines.

Developments in L2-based human papillomavirus (HPV) vaccines.

Journal: Virus research
Published: September 12, 2016

Progress and prospects for L2-based human papillomavirus vaccines.

Progress and prospects for L2-based human papillomavirus vaccines.

Journal: Expert review of vaccines
Published: February 23, 2016

Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids.

Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids.

Journal: British journal of cancer
Published: November 15, 2015

Establishment of an in vitro equine papillomavirus type 2 (EcPV2) neutralization assay and a VLP-based vaccine for protection of equids against EcPV2-associated genital tumors.

Establishment of an in vitro equine papillomavirus type 2 (EcPV2) neutralization assay and a VLP-based vaccine for protection of equids against EcPV2-associated genital tumors.

Journal: Virology
Published: May 04, 2015

A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.

A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.

Journal: PloS one
Published: September 24, 2014

Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.

Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.

Journal: The Journal of investigative dermatology
Published: March 29, 2013
Showing 1-8 of 8

Last Updated: 09/26/2026